A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Cutaneous Lupus Erythematosus
In brief
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Key facts
- Study ID
- NCT06015737
- Run by
- AstraZeneca
- People needed
- 339
- Starts
- 2024-06-29
- Expected to finish
- 2027-08-10
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Chengdu, China
- Research Site — Chongqing, China
- Research Site — Dongguan, China
- Research Site — Guangzhou, China
- Research Site — Heilongjiang, China
- Research Site — Jinan, China
- Research Site — Shanghai, China
- Research Site — Shanghai, China
- Research Site — Shenzhen, China
- Research Site — Shenzhen, China
- Research Site — Shenzhen, China
- Research Site — Ürümqi, China
- Research Site — Zhuzhou, China
- Research Site — Barranquilla, Colombia
- Research Site — Bogotá, Colombia
- Research Site — Aarhus, Denmark
- Research Site — Copenhagen, Denmark
- Research Site — Bois-Guillaume, France
- Research Site — Dijon, France
- Research Site — Lyon, France
- Research Site — Montivilliers, France
- Research Site — Nantes, France
- Research Site — Paris, France
- Research Site — Paris, France
- Research Site — Changsha, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.